Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in ApcMin/+ mice

Clinical Cancer Research

Volumn 16, Issue 23, 2010, Pages 5703-5711

  Fini, Lucia ^a,b   Piazzi, Giulia ^a,c   Ceccarelli, Claudio ^c   Daoud, Yahya ^d   Belluzzi, Andrea ^c   Munarini, Alessandra ^c   Graziani, Giulia ^e   Fogliano, Vincenzo ^e   Selgrad, Michael ^a   Garcia, Melissa ^a   Gasbarrini, Antonio ^b   Genta, Robert M ^f   Boland, C Richard ^a   Ricciardiello, Luigi ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FATTY ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER RISK; CELL PROLIFERATION; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; FATTY ACID ANALYSIS; FOOD INTAKE; LIPID PEROXIDATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA; COLONIC POLYPS; COLORECTAL NEOPLASMS; EICOSAPENTAENOIC ACID; FATTY ACIDS, NONESTERIFIED; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TUMOR BURDEN;

EID: 78650364506     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1990     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Grau MV, Rees JR, Baron JA. Chemoprevention in gastrointestinal cancers: current status. Basic Clin Pharmacol Toxicol 2006;98:281-7.
3. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82.
4. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
5. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
6. Tavani A, Pelucchi C, Parpinel M, et al. n-3 polyunsaturated fatty acid intake and cancer risk in Italy and Switzerland. Int J Cancer 2003;105:113-6. (Pubitemid 36418495)
7. Dupertuis YM, Meguid MM, Pichard C. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2007;10:427-32.
8. Chapkin RS, Seo J, McMurray DN, Lupton JR. Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids 2008;153:14-23.
9. Courtney ED, Matthews S, Finlayson C, et al. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis 2007;22:765-76.
10. Anderson BM, Ma DW. Are all n-3 polyunsaturated fatty acids created equal? Lipids Health Dis 2009;8:33.
11. Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P. Specific fatty acids and human colorectal cancer: an overview. Cancer Detect Prev 2003;27:55-66.
12. Gudbrandsen OA, Wergedahl H, Bohov P, Berge RK. The absorption, distribution and biological effects of a modified fatty acid in its free form and as an ethyl ester in rats. Chem Biol Interact 2009;179:227-32.
13. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun 1988;152:328-35.
14. Ceccarelli C, Piazzi G, Paterini P, et al. Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading. Ann Oncol 2005;16Suppl 4:iv74-9.
15. D'Argenio G, Mazzone G, Tuccillo C, et al. Apple polyphenol extracts prevent aspirin-induced damage to the rat gastric mucosa. Br J Nutr 2008;100:1228-36.
16. West NJ, Clark SK, Phillips RK, et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010;59:918-25.
17. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
18. Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1997;1332:F25-48.
19. Yamada Y, Mori H. Multistep carcinogenesis of the colon in Apc(Min/+) mouse. Cancer Sci 2007;98:6-10. (Pubitemid 44803913)
20. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract 2008;204:479-90.
21. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009;10:211-9.
22. Marshall JR. Prevention of colorectal cancer: diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am 2008;37:73-82, vi.
23. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
24. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
25. Escrich E, Solanas M, Moral R, Costa I, Grau L. Are the olive oil and other dietary lipids related to cancer? Experimental evidence. Clin Transl Oncol 2006;8:868-83.
26. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008;269:363-77.
27. Calviello G, Serini S, Piccioni E. n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Curr Med Chem 2007;14:3059-69.
28. Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br J Nutr 2008;100:1152-7.
29. Gonzalez-Periz A, Horrillo R, Ferre N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-57.
30. Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol 2009;158:960-71.
31. Tammali R, Ramana KV, Singhal SS, Awasthi S, Srivastava SK. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 2006;66:9705-13.
32. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005;310:1504-10.
33. Kopecky J, Rossmeisl M, Flachs P, et al. n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc Nutr Soc 2009;1-9.
34. Pellizzon M, Buison A, Ordiz F Jr, Santa AL , Jen KL . Effects of dietary fatty acids and exercise on body-weight regulation and metabolism in rats. Obes Res 2002;10:947-55.
35. Paulsen JE, Elvsaas IK, Steffensen IL, Alexander J. A fish oil derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl ester suppresses the formation and growth of intestinal polyps in the Min mouse. Carcinogenesis 1997;18:1905-10.
36. Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Whelan J. Highly unsaturated (n-3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce tumorigenesis in Apc (Min/+) mice. J Nutr 2000;130:2434-43.
37. Hong DD, Takahashi Y, Kushiro M, Ide T. Divergent effects of eicosapentaenoic and docosahexaenoic acid ethyl esters, and fish oil on hepatic fatty acid oxidation in the rat. Biochim Biophys Acta 2003;1635:29-36.
38. Hudson EA, Tisdale MJ. Comparison of the effectiveness of eicosapentaenoic acid administered as either the free acid or ethyl ester as an anticachectic and antitumour agent. Prostaglandins Leukot Essent Fatty Acids 1994;51:141-5.
39. Boustani S, Colette C, Monnier L, Descomps B, Crastes de PA, Mendy F. Enteral absorption in man of eicosapentaenoic acid in different chemical forms. Lipids 1987;22:711-4.
40. Hamazaki T, Urakaze M, Makuta M, et al. Intake of different eicosapentaenoic acid-containing lipids and fatty acid pattern of plasma lipids in the rats. Lipids 1987;22:994-8.
41. Krokan HE, Bjerve KS, Mork E. The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim Biophys Acta 1993;1168:59-67.
42. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun 1988;156:960-3.
43. Cheng J, Ogawa K, Kuriki K, et al. Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors. Cancer Lett 2003;193:17-24.